US 12,275,712 B2
Triterpene derivatives as HIV inhibitors
Parthasaradhi Reddy Bandi, Balanagar Hyderabad (IN); Rathnakar Reddy Kura, Balanagar Hyderabad (IN); Panduranga Reddy Adulla, Balanagar Hyderabad (IN); and Bhaskar Reddy Kasireddy, Balanagar Hyderabad (IN)
Assigned to HETERO LABS LIMITED, Balanagar Hyderabad (IN)
Appl. No. 17/430,130
Filed by HETERO LABS LIMITED, Balanagar Hyderabad (IN)
PCT Filed Feb. 11, 2020, PCT No. PCT/IB2020/051048
§ 371(c)(1), (2) Date Aug. 11, 2021,
PCT Pub. No. WO2020/165741, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. 201941005217 (IN), filed on Feb. 11, 2019.
Prior Publication US 2022/0177439 A1, Jun. 9, 2022
Int. Cl. C07D 295/13 (2006.01); A61P 31/18 (2006.01); C07D 295/26 (2006.01); C07F 7/18 (2006.01)
CPC C07D 295/13 (2013.01) [A61P 31/18 (2018.01); C07D 295/26 (2013.01); C07F 7/1804 (2013.01)] 10 Claims
 
1. A compound of the formula (I):

OG Complex Work Unit Chemistry
wherein,
R1 is selected from

OG Complex Work Unit Chemistry
R2 is selected from C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C3-C8 cycloalkyl; wherein the optional substituent is C1-C6 alkyl;
R3 is hydrogen;
R4 is selected from optionally substituted C1-C6 alkyl or —C(O)ORa; wherein C1-C6 alkyl is ethyl and the optional substituent is selected from halo, hydroxy, alkoxy, or —OC(O)CH2alkoxy;
ring

OG Complex Work Unit Chemistry
Ra is hydrogen or C1-C6 alkyl; and
Rb is C1-C6 alkyl;
or
pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, or a combination thereof.